Storia in 2 fonti

Sun Pharma Q1 Results: Profit rises 27% YoY to Rs 2,895 crore; revenue climbs 10.5%

Sun Pharma Q1 Results: Sun Pharma reported a 27% YoY rise in Q1 net profit to Rs 2,895 crore, while revenue grew 10% to Rs 15,300 crore, driven by strong performance in India and its innovative medicines business despite weak US formulations sales. EBITDA rose 3% to Rs 4,418 crore. The company highlighted semaglutide approvals and said the Organon acquisition remains on track for early 2027.

Raccontata da

economictimes.indiatimes.com

thehindubusinessline.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

economictimes.indiatimes.comStai leggendo4 h fa

Sun Pharma Q1 Results: Profit rises 27% YoY to Rs 2,895 crore; revenue climbs 10.5%

originale

thehindubusinessline.com4 h fa

Sun Pharma posts higher quarterly profit on strong demand

Sun Pharma +27% Q1 net profit (₹2,895 cr), driven by specialty medicines surge (+12.8% YoY): skin, cancer, obesity segment strength. $11.75B Organon acquisition accelerates pivot from low-margin generics to high-margin specialty, offsetting US market headwinds.

Timeline cronologica

venerdì 31 luglio 2026·economictimes.indiatimes.com
Sun Pharma Q1 Results: Profit rises 27% YoY to Rs 2,895 crore; revenue climbs 10.5%
Sun Pharma Q1 Results: Sun Pharma reported a 27% YoY rise in Q1 net profit to Rs 2,895 crore, while revenue grew 10% to Rs 15,300 crore, driven by strong performance in India and…
venerdì 31 luglio 2026·thehindubusinessline.com
Sun Pharma posts higher quarterly profit on strong demand
Consolidated net profit in Q1 rises to ₹2,895 crore ($303.54 million) from ₹2,279 crore a year earlier